Clinical Trials
404
Active:17
Completed:51
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:16
Phase 2:86
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (228 trials with phase data)• Click on a phase to view related trials
Phase 2
86 (37.7%)Not Applicable
85 (37.3%)Phase 3
22 (9.6%)Phase 1
16 (7.0%)Phase 4
15 (6.6%)Early Phase 1
4 (1.8%)Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
Not yet recruiting
- Conditions
- Ovarian CancerAntibody-drug ConjugatesClear Cell Adenocarcinoma of Ovary
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Target Recruit Count
- 22
- Registration Number
- NCT07168083
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Not Applicable
Not yet recruiting
- Conditions
- Cervical Cancer MetastaticCervical Cancer Recurrent
- Interventions
- Drug: Famitinib + Camrelizumab
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Target Recruit Count
- 120
- Registration Number
- NCT07143292
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Not Applicable
Not yet recruiting
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)Neoadjuvant Chemoimmunotherapy
- Interventions
- Drug: Preoperative neoadjuvant immunotherapy chemotherapyDrug: Two courses of preoperative neoadjuvant immunotherapy chemotherapyDrug: Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Target Recruit Count
- 70
- Registration Number
- NCT07137858
OPtimizing REperfusion by Intra-Arterial ThRomboLysis as Adjunct to Endovascular Treatment for Medium Vessel Occlusion
Not Applicable
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Target Recruit Count
- 530
- Registration Number
- NCT07137832
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
Not Applicable
Not yet recruiting
- Conditions
- Symptomatic Intracranial Atherosclerotic Stenosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Target Recruit Count
- 5276
- Registration Number
- NCT07119918
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 81
- Next
News
No news found